Please login to the form below

Not currently logged in
Email:
Password:

ChemoCentryx

This page shows the latest ChemoCentryx news and features for those working in and with pharma, biotech and healthcare.

GSK hands back rights to ChemoCentryx drug

GSK hands back rights to ChemoCentryx drug

GSK licensed rights to vercirnon (also known as Traficet-EN and CCX282) in 2010 as an extension to a wide-ranging deal with ChemoCentryx for four anti-inflammatory drugs. ... GSK dropped another drug from the initial collaboration earlier this year, but

Latest news

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Growth for vedolizumab and other new entrants such as Johnson &Johnson's interleukin-23 inhibitor Stelara (ustekinumab) and GlaxoSmithKline/ChemoCentryx' vercirnon in Crohn's - and Pfizer's JAK inhibitor tofacitinib in

  • GSK to tackle inflammatory bowel disease

    GSK has exercised an option to further develop ChemoCentryx's Traficet-EN (CCX282-B)  for the treatment of inflammatory bowel disease. ... Under the terms of the collaboration, ChemoCentryx will receive an option exercise fee of $35m and may be

  • Pharma news in brief

    ChemoCentryx will receive an upfront payment of $63.5m in both cash and an equity investment. ... The collaboration covers several projects, including ChemoCentryx's drug, Traficet-EN, which is already in late-stage development for inflammatory bowel

  • A bright start

    The group has formed a strategic alliance with US-based ChemoCentryx to develop and market treatments for various inflammatory disorders in a licensing deal that could be worth up to ... ChemoCentryx is to receive an upfront $63.5m payment comprising

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the complement 5a receptor (C5aR) for ... In return for the expanded territory, Vifor is paying

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics